Femasys Inc

Femasys COO John C. Canning’s 150k options grant—no cash outlay—signals insider confidence amid falling shares, $12M funding, and advancing FemVue clinical trials.

Femasys CEO’s insider RSU purchases signal strong confidence in a Swiss partnership and future pipeline, offering a long‑term upside despite current volatility.